High-Frequency Monitoring for Early Detection of Cisplatin Ototoxicity

Stephen A. Fausti, James A. Henry, Heidi I. Schaffer, Deanna J. Olson, Richard H. Frey, Grover C. Bagby

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Cisplatin can cause irreversible hearing loss initially detectable as impairment of high-frequency hearing with progression to lower frequencies. Many patients receiving cisplatin are too ill to tolerate lengthy audiometric testing. Therefore, a rapid and sensitive high-frequency monitoring strategy to detect cisplatin-induced ototoxicity is needed. Serial conventional (0.25 to 8 kHz) and high-frequency (≥8 kHz) threshold monitoring was performed in patients receiving cisplatin, resulting in 84% of ears showing hearing loss, of which 71% were detected first in frequencies of 8 kHz or greater. By analysis according to an individualized, specific high-frequency range, early identification of hearing loss occurred in 94% of ears showing change. This five-frequency procedure is a sensitive detector of ototoxicity and is proposed as an alternative monitoring protocol for patients receiving cisplatin who cannot tolerate extended testing. (Arch Otolaryngol Head Neck Surg. 1993;119:661-666).

Original languageEnglish (US)
Pages (from-to)661-666
Number of pages6
JournalArchives of Otolaryngology--Head and Neck Surgery
Issue number6
StatePublished - Jun 1993

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology


Dive into the research topics of 'High-Frequency Monitoring for Early Detection of Cisplatin Ototoxicity'. Together they form a unique fingerprint.

Cite this